BAGANBAZAR GRAPHEXPLORE · ANALYZE · GROW
Theme
LiveDesk
World/Source-attributed reporting

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
ORIGINAL SOURCE

Consumer News and Business Channel

This report is indexed by BAGANBAZAR GRAPH with its original publisher named and linked for readers.

Read at original outlet ↗